Bosutinib-d8

• UNSPSC Description:

  Bosutinib-d8 is a deuterium labeled Bosutinib. Bosutinib is a dual Src/Abl inhibitor with IC50s of 1.2 nM and 1 nM, respectively[1][2].

• Target Antigen:

  Autophagy; Bcr-Abl; Isotope-Labeled Compounds; Src

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Autophagy;Others;Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Purity:

  99.0

• Solubility:

  10 mM in DMSO

• Smiles:

  CN1C([2H])([2H])C([2H])([2H])N(C([2H])([2H])C1([2H])[2H])CCCOC2=C(C=C3C(NC4=CC(OC)=C(C=C4Cl)Cl)=C(C=NC3=C2)C#N)OC

• Molecular Weight:

  538.50

• References & Citations:

  [1]Boschelli DH, et al. Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity. J Med Chem, 2001, 44(23), 3965-3977.|[2]Golas JM, et al. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res, 2003, 63(2), 375-381.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported